Last updated: October 7, 2026
ecutive summary: CHLORAPREP One-Step is BD’s branded skin-preparation product containing 2% chlorhexidine gluconate in 70% isopropyl alcohol. Its commercial position rests on hospital protocol adoption, infection-prevention requirements, applicator convenience, and BD’s integrated acute-care sales channel. BD does not report CHLORAPREP One-Step revenue, gross margin, unit volume, or geographic sales separately. The product’s financial trajectory therefore must be assessed through BD’s broader portfolio results and market drivers rather than a standalone public model.
CHLORAPREP One-Step Market Dynamics, Financial Trajectory, and Competitive Position
What is CHLORAPREP One-Step and how is it regulated?
CHLORAPREP One-Step is a preoperative and procedural antiseptic applicator marketed by Becton, Dickinson and Company, or BD. The principal formulation is 2% chlorhexidine gluconate, or CHG, in 70% isopropyl alcohol, commonly described as 2% CHG/70% IPA.
The product is used for:
- Surgical-site skin preparation
- Central-line and vascular-access procedures
- Intravascular catheter insertion
- Injection and other invasive procedures
- General hospital skin antisepsis
CHLORAPREP is a topical antiseptic product rather than a conventional prescription drug. Its regulatory position is based primarily on FDA over-the-counter antiseptic and device requirements, product labeling, manufacturing controls, and applicable 510(k) clearances for applicator configurations. The applicator is a major part of the commercial product because it controls dose, application area, activation, and user workflow.
| Attribute |
CHLORAPREP One-Step |
| Manufacturer |
Becton, Dickinson and Company |
| Active ingredients |
Chlorhexidine gluconate and isopropyl alcohol |
| Common formulation |
2% CHG in 70% IPA |
| Product type |
Topical antiseptic and preoperative skin-preparation system |
| Primary customers |
Hospitals, ambulatory surgery centers, clinics and procedural facilities |
| Main purchasing criteria |
Clinical protocol, infection prevention, applicator design, supply reliability and price |
| Public standalone revenue |
Not disclosed |
| Orange Book status |
Not generally treated as a conventional Orange Book-listed prescription medicine |
FDA has recognized alcohol-based CHG preparations as important antiseptic products for surgical and procedural use, subject to labeling, safety and manufacturing requirements. The FDA’s 2017 final rule addressed nonprescription consumer antiseptic products and distinguished healthcare antiseptic products that require additional data and regulatory review (U.S. Food and Drug Administration, 2017).
How large is the market for CHLORAPREP One-Step?
The addressable market is the global healthcare antiseptic and procedural skin-preparation market. Demand is concentrated in hospitals and other facilities that perform surgery, catheter placement, vascular access, injections or other invasive procedures.
The market is supported by four structural factors:
- Hospitals use standardized skin-preparation protocols.
- Infection-prevention programs favor products with established clinical evidence.
- Prepackaged applicators reduce preparation time and variation.
- Large healthcare systems prefer suppliers capable of providing national or regional contracts.
Growth is constrained by product substitution, hospital purchasing pressure, generic and private-label CHG/IPA products, and periodic shortages of alcohol, chlorhexidine, packaging components or applicator assemblies.
The most important demand variable is procedure volume. Elective surgery, interventional cardiology, oncology infusion, dialysis access, emergency care and inpatient catheter utilization all influence consumption. A reduction in elective procedures can lower short-term demand. Higher procedural complexity and increased use of vascular devices can increase consumption per patient.
Public sources do not provide a reliable standalone market share for CHLORAPREP One-Step. Market reports often combine surgical antiseptics, hand antiseptics, skin disinfectants and other healthcare infection-control products, making narrow product-level share estimates difficult to validate.
What is the financial trajectory of CHLORAPREP One-Step?
BD does not separately disclose CHLORAPREP One-Step sales. It reports results at broader operating-segment levels, which prevents direct calculation of product revenue, EBITDA, margin, retention rate or regional growth.
BD’s consolidated revenue increased from approximately $19.4 billion in fiscal 2023 to approximately $20.2 billion in fiscal 2024, according to the company’s annual reporting. That growth reflects BD’s full portfolio, including medical devices, medication management, diagnostics and life-science products. It cannot be attributed specifically to CHLORAPREP (Becton, Dickinson and Company, 2024).
| Financial indicator |
Publicly available position |
| CHLORAPREP One-Step annual revenue |
Not separately disclosed |
| CHLORAPREP One-Step operating profit |
Not separately disclosed |
| Unit volume |
Not separately disclosed |
| Average selling price |
Not separately disclosed |
| BD fiscal 2023 revenue |
Approximately $19.4 billion |
| BD fiscal 2024 revenue |
Approximately $20.2 billion |
| Product-level forecast |
Requires nonpublic sales, volume and pricing data |
The product’s likely financial profile is that of a recurring consumables business. Revenue depends on repeat use rather than a one-time capital purchase. This supports relatively predictable demand when products are written into hospital protocols, although pricing remains vulnerable to tenders and group purchasing organization negotiations.
The most relevant financial levers are:
- Procedure and admission volume
- Contract wins and losses
- Price increases and inflation recovery
- Product mix between standard and premium applicators
- Supply availability
- Manufacturing utilization
- Conversion from competitor or generic products
- Hospital budget pressure
A premium branded product can protect price where clinical protocols, nursing workflow and infection-prevention committees favor a specified product. That protection weakens when hospitals permit therapeutically equivalent alternatives.
Which companies compete with CHLORAPREP One-Step?
CHLORAPREP competes with branded, generic and private-label skin-preparation products. The competitive set includes products from 3M, Cardinal Health, Medline Industries, McKesson suppliers and regional medical-supply manufacturers.
Principal competitive categories
| Competitive category |
Typical formulation or proposition |
Competitive effect |
| Branded CHG/alcohol applicators |
Often 2% CHG/70% IPA |
Direct clinical and workflow competition |
| Generic CHG/IPA products |
Comparable antiseptic formulation |
Price pressure and formulary substitution |
| Povidone-iodine products |
Alternative antiseptic chemistry |
Used where CHG is unsuitable or restricted |
| Alcohol-only products |
Lower-cost preparation option |
Relevant in selected procedures and protocols |
| Bulk or nonintegrated solutions |
Separate solution and applicator |
Lower acquisition cost but more preparation steps |
3M’s surgical skin-preparation products, including DuraPrep and SoluPrep lines in relevant markets, compete through brand recognition, procedural familiarity and hospital contracts. Cardinal Health and Medline compete through distribution scale, private-label offerings and purchasing relationships. Local suppliers may compete on price, availability and tender flexibility.
BD has an advantage where CHLORAPREP is embedded in a broader hospital account relationship involving vascular-access devices, medication-management products, infusion equipment or infection-prevention supplies. That advantage does not eliminate competitive risk because hospitals frequently divide purchasing among multiple suppliers.
What clinical and regulatory factors support demand?
Clinical guidance has favored alcohol-based formulations, particularly CHG in alcohol, for many invasive procedures when there is no contraindication. The Centers for Disease Control and Prevention recommends appropriate antiseptic skin preparation before central venous catheter insertion and identifies chlorhexidine preparations as a key option in infection-prevention protocols (Centers for Disease Control and Prevention, 2011).
Demand also benefits from:
- Standardized operating-room protocols
- Central-line-associated bloodstream infection reduction programs
- Surgical-site infection surveillance
- Hospital accreditation requirements
- Increasing use of prefilled and single-use applicators
- Pressure to reduce preparation errors
Safety restrictions limit use in some populations and applications. Chlorhexidine can cause serious allergic reactions, and its use may require caution in neonates, premature infants, mucosal applications and patients with known sensitivity. Alcohol-based products also require drying before ignition-risk procedures and careful handling around electrosurgical equipment. Labeling and institutional protocols therefore affect product selection.
What manufacturing and supply-chain barriers affect CHLORAPREP?
The manufacturing barrier is moderate rather than absolute. The core chemistry is established, but reliable commercial production requires control of:
- Pharmaceutical-grade chlorhexidine
- Isopropyl alcohol supply
- Nonwoven applicator materials
- Plastic components and packaging
- Sterility or bioburden controls, where applicable
- Fill-volume accuracy
- Container-closure integrity
- Flammability and transport requirements
- Quality-system compliance
The applicator is commercially important. A competing product with the same active ingredients can still face adoption barriers if its applicator produces inconsistent coverage, leaks, activates poorly or requires more preparation time.
Supply disruption is a material risk because hospitals generally hold limited inventory for high-use consumables. Shortages can create rapid switching to alternative products. Once hospitals validate a substitute and revise protocols, some displaced volume may not return immediately.
What patent and exclusivity protection does CHLORAPREP One-Step have?
CHLORAPREP’s protection is unlikely to depend primarily on a single long-lived composition-of-matter patent. The active ingredients are established antiseptic compounds, and the commercial product is more likely protected through a combination of:
- Product trademarks
- Applicator and packaging designs
- Manufacturing know-how
- Regulatory dossiers
- Quality-system capabilities
- Distribution contracts
- Clinical evidence and protocol placement
- Potential formulation, container or delivery-system patents
CHLORAPREP One-Step is not generally analyzed like a new molecular entity with an Orange Book patent estate and Hatch-Waxman exclusivity period. Generic entry can occur through competing antiseptic products that use the same or similar active ingredients, subject to FDA requirements and applicable monograph or clearance pathways.
The practical barrier is therefore commercial and operational. A competitor must achieve regulatory compliance, stable supply, acceptable packaging, hospital approval and distributor access. Those barriers can delay substitution but do not provide the same exclusivity profile as a valid composition patent.
What is the generic entry risk for CHLORAPREP One-Step?
Generic and private-label risk is medium to high at the formulation level and lower at the account-conversion level.
A product containing the same CHG and alcohol concentrations can compete directly on price. However, hospitals may require:
- Product evaluation by infection-control committees
- Nursing and operating-room training
- Compatibility review with procedure kits
- Validation of drying and application times
- Supply-chain qualification
- Contracting approval
- Changes to electronic preference cards or standard order sets
The strongest risk arises during hospital-wide cost-reduction initiatives, competitive group purchasing events and supply shortages. The risk is lower when CHLORAPREP is specified in a procedure kit, linked to a broader BD contract or supported by established clinical protocols.
What licensing deals and litigation affect CHLORAPREP?
No major public licensing transaction or product-specific litigation can be reliably assigned to CHLORAPREP One-Step from BD’s standard public disclosures. BD’s acquisition of CareFusion in 2015 brought the CareFusion product portfolio, including CHLORAPREP, into BD’s operations. The transaction expanded BD’s medication-management and infection-prevention portfolio (Becton, Dickinson and Company, 2015).
No product-specific Paragraph IV litigation framework is expected to be central to CHLORAPREP because the product is not a conventional prescription drug with an Orange Book patent listing. Competitive disputes are more likely to involve trademarks, trade dress, product liability, supply contracts, procurement awards or regulatory compliance.
How does CHLORAPREP compare with povidone-iodine products?
| Factor |
CHLORAPREP One-Step |
Povidone-iodine preparation |
| Core chemistry |
Chlorhexidine plus alcohol |
Iodophor, often aqueous or alcohol-based |
| Main advantage |
Fast broad-spectrum preparation and established procedural use |
Alternative where CHG is unsuitable |
| Key limitation |
Allergy, neonatal and mucosal-use restrictions; flammability |
Slower or different drying profile depending on formulation |
| Commercial position |
Premium branded applicator opportunity |
Broad generic and branded competition |
| Switching risk |
Hospitals may substitute based on protocol and price |
Selected as alternative for contraindicated patients or procedures |
The comparison is procedure-specific. CHLORAPREP is strongest where hospitals prioritize alcohol-based CHG protocols and prefilled applicator convenience. Povidone-iodine remains important where CHG sensitivity, patient age, anatomical site or institutional policy limits use.
What is the investment and commercial outlook?
CHLORAPREP One-Step has a stable, recurring-consumables profile rather than a high-growth specialty-pharmaceutical profile. Revenue growth is most likely to come from price, procedure volume, account penetration and conversion from competing products.
Upside drivers
- Growth in surgical and interventional procedures
- Greater use of standardized prefilled applicators
- Hospital focus on catheter-related infection reduction
- Cross-selling through BD’s acute-care portfolio
- Premium pricing for workflow and supply reliability
- Expansion in emerging healthcare systems
Downside drivers
- Hospital purchasing consolidation
- Private-label substitution
- Aggressive tender pricing
- Supply interruptions
- Reduced elective procedure volume
- Safety-related restrictions
- Competitor products with equivalent CHG/IPA concentrations
The principal financial conclusion is that CHLORAPREP is strategically valuable as a recurring hospital consumable, but its standalone contribution cannot be quantified from public financial statements. BD’s broader revenue growth provides evidence of corporate scale, not a product-specific earnings forecast.
Key takeaways
- CHLORAPREP One-Step is a BD antiseptic applicator based on 2% CHG in 70% IPA.
- Its market is driven by hospital procedures, infection-prevention protocols and recurring consumable demand.
- BD does not disclose product-level revenue, margin, volume or market share.
- The product is not primarily protected by conventional pharmaceutical exclusivity.
- Competitive risk comes from generic, private-label and alternative antiseptic products.
- BD’s distribution platform and hospital relationships support retention and account expansion.
- The principal financial risks are tender pricing, substitution, supply disruption and procedural-volume declines.
- The product’s outlook is stable but modestly growth-oriented, with value concentrated in recurring hospital utilization and portfolio cross-selling.
FAQs about CHLORAPREP One-Step
Is CHLORAPREP One-Step a prescription drug?
No. It is a topical healthcare antiseptic product and applicator system. Its regulatory framework differs from that of a conventional prescription medicine approved through an NDA.
Does CHLORAPREP One-Step have Orange Book patents?
CHLORAPREP One-Step is not generally treated as an Orange Book-listed prescription drug with Hatch-Waxman exclusivity. Protection is more likely to involve trademarks, delivery-system design, know-how and regulatory compliance.
Who manufactures CHLORAPREP One-Step?
Becton, Dickinson and Company manufactures and markets the CHLORAPREP product line. The portfolio entered BD through its acquisition of CareFusion.
What is the main alternative to CHLORAPREP One-Step?
The main alternatives are other CHG-in-alcohol applicators, including branded and private-label products, and povidone-iodine preparations where chlorhexidine is unsuitable.
Can CHLORAPREP One-Step revenue be modeled from BD’s annual report?
Not with precision. BD reports at broader segment and company levels and does not separately identify CHLORAPREP revenue, units, pricing or profitability.
References
-
Becton, Dickinson and Company. (2015). BD completes acquisition of CareFusion. BD.
-
Becton, Dickinson and Company. (2024). 2024 annual report. U.S. Securities and Exchange Commission.
-
Centers for Disease Control and Prevention. (2011). Guidelines for the prevention of intravascular catheter-related infections. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2017). Safety and effectiveness of consumer antiseptics; topical antimicrobial drug products for over-the-counter human use. Federal Register, 82 Fed. Reg. 7644.
-
Becton, Dickinson and Company. (n.d.). ChloraPrep patient preoperative skin preparation. BD.
